Literature DB >> 16481883

Renal and vascular hypertension-induced inflammation: role of angiotensin II.

Marta Ruiz-Ortega1, Vanesa Esteban, Mónica Rupérez, Elsa Sánchez-López, Juan Rodríguez-Vita, Gisselle Carvajal, Jesús Egido.   

Abstract

PURPOSE OF REVIEW: We will focus on the recent findings concerning the inflammatory response in vascular and renal tissues caused by hypertension. RECENT
FINDINGS: Angiotensin II is one of the main factors involved in hypertension-induced tissue damage. This peptide regulates the inflammatory process. Angiotensin II activates circulating cells, and participates in their adhesion to the activated endothelium and subsequent transmigration through the synthesis of adhesion molecules, chemokines and cytokines. Among the intracellular signals involved in angiotensin II-induced inflammation, the production of reactive oxygen species and the activation of nuclear factor-kappaB are the best known.
SUMMARY: The pharmacological blockade of angiotensin II actions, by angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists, results in beneficial organ protective effects, in addition to the effects of these agents on blood pressure control, that can be explained by the blockade of the angiotensin II-induced pro-inflammatory response. These data provide a rationale for the use of blockers of the renin-angiotensin system to prevent vascular and renal inflammation in patients with hypertension.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16481883     DOI: 10.1097/01.mnh.0000203190.34643.d4

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  38 in total

1.  The C-terminal module IV of connective tissue growth factor, through EGFR/Nox1 signaling, activates the NF-κB pathway and proinflammatory factors in vascular smooth muscle cells.

Authors:  Raúl R Rodrigues-Diez; Ana Belen Garcia-Redondo; Macarena Orejudo; Raquel Rodrigues-Diez; Ana Maria Briones; Enrique Bosch-Panadero; Gyorgy Kery; Janos Pato; Alberto Ortiz; Mercedes Salaices; Jesus Egido; Marta Ruiz-Ortega
Journal:  Antioxid Redox Signal       Date:  2015-01-01       Impact factor: 8.401

2.  Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation.

Authors:  Mahmut Ilker Yilmaz; Juan Jesús Carrero; Jose Luis Martín-Ventura; Alper Sonmez; Mutlu Saglam; Turgay Celik; Halil Yaman; Mujdat Yenicesu; Tayfun Eyileten; Juan Antonio Moreno; Jesús Egido; Luis Miguel Blanco-Colio
Journal:  Clin J Am Soc Nephrol       Date:  2010-04-29       Impact factor: 8.237

3.  Role of Angiotensin II type 1 receptor on renal NAD(P)H oxidase, oxidative stress and inflammation in nitric oxide inhibition induced-hypertension.

Authors:  J Rincón; D Correia; J L Arcaya; E Finol; A Fernández; M Pérez; K Yaguas; E Talavera; M Chávez; R Summer; F Romero
Journal:  Life Sci       Date:  2015-01-24       Impact factor: 5.037

4.  Cellular and molecular responses of the basilar terminus to hemodynamics during intracranial aneurysm initiation in a rabbit model.

Authors:  John Kolega; Ling Gao; Max Mandelbaum; J Mocco; Adnan H Siddiqui; Sabareesh K Natarajan; Hui Meng
Journal:  J Vasc Res       Date:  2011-05-31       Impact factor: 1.934

Review 5.  The role of cell plasticity in progression and reversal of renal fibrosis.

Authors:  Jean-Claude Dussaule; Dominique Guerrot; Anne-Cécile Huby; Christos Chadjichristos; Nasim Shweke; Jean-Jacques Boffa; Christos Chatziantoniou
Journal:  Int J Exp Pathol       Date:  2011-02-12       Impact factor: 1.925

6.  Secreted protein acidic and rich in cysteine deficiency ameliorates renal inflammation and fibrosis in angiotensin hypertension.

Authors:  Matthew J Socha; Marlina Manhiani; Neveen Said; John D Imig; Kouros Motamed
Journal:  Am J Pathol       Date:  2007-08-23       Impact factor: 4.307

7.  Relationship of inflammation and endothelial dysfunction with risks to cardiovascular disease among people in Inner Mongolia of China.

Authors:  Hao Peng; Shu Hai Han; Hai Ying Liu; Vasisht Chandni; Xiao Qing Cai; Yong Hong Zhang
Journal:  Biomed Environ Sci       Date:  2013-10       Impact factor: 3.118

Review 8.  A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme.

Authors:  Kenneth E Bernstein; Frank S Ong; Wendell-Lamar B Blackwell; Kandarp H Shah; Jorge F Giani; Romer A Gonzalez-Villalobos; Xiao Z Shen; Sebastien Fuchs; Rhian M Touyz
Journal:  Pharmacol Rev       Date:  2012-12-20       Impact factor: 25.468

9.  Intrarenal angiotensin II and angiotensinogen augmentation in chronic angiotensin II-infused mice.

Authors:  Romer A Gonzalez-Villalobos; Dale M Seth; Ryousuke Satou; Heather Horton; Naro Ohashi; Kayoko Miyata; Akemi Katsurada; Duy V Tran; Hiroyuki Kobori; L G Navar
Journal:  Am J Physiol Renal Physiol       Date:  2008-06-25

10.  Role of inflammation in the development of renal damage and dysfunction in angiotensin II-induced hypertension.

Authors:  Tang-Dong Liao; Xiao-Ping Yang; Yun-He Liu; Edward G Shesely; Maria A Cavasin; William A Kuziel; Patrick J Pagano; Oscar A Carretero
Journal:  Hypertension       Date:  2008-06-09       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.